Stockreport

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics, Inc.  (QNCX) 
PDF Phase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quart [Read more]